Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease

European Journal of Immunology

Volumn 36, Issue 4, 2006, Pages 930-939

  Fontenot, Andrew P ^a   Edwards, David M ^b,c   Chou, Yuan K ^b,c   Mack, Douglas G ^a   LaTocha, Dorian ^b,c   Vandenbark, Arthur A ^b,c   Burrows, Gregory G ^b,c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic beryllium disease; Inflammation; Lung; T lymphocytes

Indexed keywords

B7 ANTIGEN; BERYLLIUM; CD134 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA DP ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN PURIFICATION; APOPTOSIS; ARTICLE; BERYLLIOSIS; CELL INTERACTION; CELL LINE; CELL SURVIVAL; CHRONIC DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG FLUID; LUNG GRANULOMA; LUNG LAVAGE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANTIGEN PRESENTATION; BERYLLIOSIS; BERYLLIUM; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645909903     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200526075     Document Type: Article

References (39)

1. Newman, L. S. and Maier, L. A., Beryllium disease.In Schwarz, M. I. and King, T. E., Jr (Eds.) Interstitial lung disease. 4th Edn. B. C. Decker Inc., Hamilton 2003, pp 435-451.
2. Newman, L. S., Bobka, C., Schumacher, B., Daniloff, E., Zhen, B., Mroz, M. and King, T. E., Jr., Compartmentalized immune response reflects clinical severity of beryllium disease. Am. J. Respir. Crit. Care Med. 1994. 150: 135-142.
3. Fontenot, A. P., Falta, M. T., Freed, B. M., Newman, L. S. and Kotzin, B. L., Identification of pathogenic T cells in patients with beryllium-induced lung disease. J. Immunol. 1999. 163: 1019-1026.
4. Richeldi, L., Sorrentino, R. and Saltini, C., HLA-DPB1 glutamate 69: A genetic marker of beryllium disease. Science 1993. 262: 242-244.
5. Richeldi, L., Kreiss, K., Mroz, M. M., Zhen, B., Tartoni, P. and Saltini, C., Interaction of genetic and exposure factors in the prevalence of berylliosis. Am. J. Ind. Med. 1997. 32: 337-340.
6. Wang, Z., White, P. S., Petrovic, M., Tatum, O. L., Newman, L. S., Maier, L. A. and Marrone, B. L., Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J. Immunol. 1999. 163: 1647-1653.
7. Maier, L. A., McGrath, D. S., Sato, H., Lympany, P., Welsh, K., Du Bois, R., Silveira, L. et al., Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J. Immunol. 2003. 171: 6910-6918.
8. Fontenot, A. P. and Maier, L. A., Genetic susceptibilty and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 2005. 26:543-549.
9. Rossman, M. D., Stubbs, J., Lee, C. W., Argyris, E., Magira, E. and Monos, D., Human leukocyte antigen class II amino acid epitopes: Susceptibility and progression markers for beryllium hypersensitivity. Am. J. Respir. Crit. Care Med. 2002. 165: 788-794.
10. Amicosante, M., Berretta, F., Rossman, M., Butler, R. H., Rogliani, P., van den Berg-Loonen, E. and Saltini, C., Identification of HLA-DRPheβ47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir. Res. 2005. 6: 94.
11. + T cells is dependent on a single amino acid of the MHC class II β-chain. J. Immunol. 2005. 175:7029-7037.
12. Rossman, M. D., Kern, J. A., Elias, J. A., Cullen, M. R., Epstein, P. E., Preuss, O. P., Markham, T. N. and Daniele, R. P., Proliferative response of bronchoalveolar lymphocytes to beryllium. Ann. Intern. Med. 1988. 108: 687-693.
13. + T cells underlies disease susceptibility HLA-DP alleles in chronic beryllium disease. Proc. Natl. Acad. Sci. USA 2000. 97: 12717-12722.
14. Fontenot, A. P., Kotzin, B. L., Comment, C. E. and Newman, L. S., Expansions of T-cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 1998. 18: 581-589.
15. + T cells in patients with chronic beryllium disease. J. Clin. Invest. 2002. 110: 1473-1482.
16. Kreiss, K., Wasserman, S., Mroz, M. M. and Newman, L. S., Beryllium disease screening in the ceramics industry: Blood test performance and exposure-disease relations. J. Occup. Med. 1993. 35: 267-274.
17. Kreiss, K., Mroz, M. M., Zhen, B., Martyny, J. W. and Newman, L. S., Epidemiology of beryllium sensitization and disease in nuclear workers. Am. Rev. Respir. Dis. 1993. 148: 985-991.
18. Lombardi, G., Germain, C., Uren, J., Fiorillo, M. T., du Bois, R. M., Jones-Williams, W., Saltini, C., Sorrentino, R. and Lechler, R., HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J. Immunol. 2001. 166: 3549-3555.
19. Tinkle, S. S., Kittle, L. A., Schumacher, B. A. and Newman, L. S., Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 1997. 158: 518-526.
20. Kreiss, K., Newman, L. S., Mroz, M. and Campbell, P. A., Screening blood test identifies subclinical beryllium disease. J. Occup. Med. 1989. 31: 603-608.
21. Mroz, M. M., Kreiss, K., Lezotte, D. C., Campbell, P. A. and Newman, L. S., Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J. Allergy Clin. Immunol. 1991. 88: 54-60.
22. Eisenbud, M. and Lisson, J., Epidemiological aspects of beryllium-induced nonmalignant lung disease: A 30-year update. J. Occup. Med. 1983. 25: 196-202.
23. Newman, L. S., Kreiss, K., King, T. E., Jr., Seay, S. and Campbell, P. A., Pathologic and immunologic alterations in early stages of beryllium disease: Re-examination of disease definition and natural history. Am. Rev. Respir. Dis. 1989. 139: 1479-1486.
24. + T cells. J. Clin. Invest. 2003. 112: 776-784.
25. Croft, M., Bradley, L. M. and Swain, S. L., Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J. Immunol. 1994. 152: 2675-2685.
26. Croft, M., Activation of naive, memory and effector T cells. Curr. Opin. Immunol. 1994. 6: 431-437.
27. Garcia, G., Komagata, Y., Slavin, A. J., Maron, R. and Weiner, H. L., Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J. Autoimmun. 1999. 13: 315-324.
28. + T cells. J. Immunol. 2000. 164: 265-272.
29. Amicosante, M., Berretta, F., Franchi, A., Rogliani, P., Dotti, C., Losi, M., Dweik, R. and Saltini, C., HLA-DP-unrestricted TNF-α release in beryllium-stimulated peripheral blood mononuclear cells. Eur. Respir. J. 2002. 20: 1174-1178.
30. Chou, Y. K., Edwards, D. M., Weinberg, A. D., Vandenbark, A. A., Kotzin, B. L., Fontenot, A. P. and Burrows, G. G., Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis. J. Immunol. 2005. 174: 4316-4324.
31. Mannie, M. D., T cell-mediated antigen presentation: A potential mechanism of infectious tolerance. Immunol. Res. 2001. 23: 1-21.
32. Nisini, R., Matricardi, P. M., Fattorossi, A., Biselli, R. and D'Amelio, R., Presentation of superantigen by human T cell clones: A model of T-T cell interaction. Eur. J. Immunol. 1992. 22: 2033-2039.
33. Nisini, R., Fattorossi, A., Ferlini, C. and D'Amelio, R., One cause for the apparent inability of human T cell clones to function as professional superantigen-presenting cells is autoactivation. Eur. J. Immunol. 1996. 26: 797-803.
34. Brod, S. A., Purvee, M., Benjamin, D. and Hafler, D. A., T-T cell interactions are mediated by adhesion molecules. Eur. J. Immunol. 1990. 20: 2259-2268.
35. Shimaoka, M., Lu, C., Palframan, R. T., von Andrian, U. H., McCormack, A., Takagi, J. and Springer, T. A., Reversibly locking a protein fold in an active conformation with a disulfide bond: Integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc. Natl. Acad. Sci. USA 2001. 98: 6009-6014.
36. Borghans, J. A., Taams, L. S., Wauben, M. H. and de Boer, R. J., Competition for antigenic sites during T cell proliferation: A mathematical interpretation of in vitro data. Proc. Natl. Acad. Sci. USA 1999. 96: 10782-10787.
37. Barna, B. P., Culver, D. A., Yen-Lieberman, B., Dweik, R. A. and Thomassen, M. J., Clinical application of beryllium lymphocyte proliferation testing. Clin. Diagn. Lab. Immunol. 2003. 10: 990-994.
38. Saunders, B. M. and Cooper, A. M., Restraining mycobacteria: Role of granulomas in mycobacterial infections. Immunol. Cell Biol. 2000. 78: 334-341.
39. Amicosante, M., Sanarico, N., Berretta, F., Arroyo, J., Lombardi, G., Lechler, R., Colizzi, V. and Saltini, C., Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate β69. Hum. Immunol. 2001. 62: 686-693.